Core Viewpoint - The valuation of Nohow Health has been significantly reduced by multiple public funds, with Dachen Fund recently announcing a valuation of HKD 0.55 per share, marking the lowest valuation to date [1][3]. Valuation Adjustments - Dachen Fund's valuation of Nohow Health has been adjusted multiple times since its suspension in March 2024, dropping from HKD 14.14 per share to HKD 0.55 per share, representing a decline of over 96% [3][5]. - Other public funds, including Baoying, Penghua, and Bosera, have also reduced their valuations of Nohow Health, with Bosera maintaining a valuation of HKD 3.33 per share, which is still above HKD 2 per share [3][6]. Market Context - Nohow Health was once a leading stock in the Hong Kong market for cancer screening, with a market capitalization exceeding HKD 40 billion [5]. - The company has faced scrutiny over financial fraud allegations, leading to its suspension and inability to disclose timely financial reports [5][6]. Fund Management Perspective - The adjustments in valuation by fund managers aim to ensure the fairness and accuracy of fund net values, protecting investor interests [4][5]. - Continuous downward adjustments reflect a pessimistic outlook on Nohow Health's prospects for resumption of trading and heightened market vigilance regarding potential risks [6].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.24% as of August 1, 2025, with mixed performance among constituent stocks [1] - Out of the constituent stocks, Aotewi led the gains with an increase of 7.18%, while Yuanjie Technology experienced the largest decline at 6.20% [1] - The Huaxia Sci-Tech 100 ETF (588800) saw a slight decrease of 0.28%, with a latest price of 1.06 yuan, but had a cumulative increase of 1.53% over the past week [1] Group 2 - The National Healthcare Security Administration (NHSA) has introduced a new pricing mechanism for newly listed drugs to support innovation in pharmaceuticals and medical devices, adding over 100 pricing items related to new medical technologies [1] - The NHSA aims to streamline the pricing and reimbursement process for new technologies and products, facilitating quicker returns on investment for clinically urgent innovations [1] - According to Zhongyin Securities, the national drug procurement has conducted 10 batches covering 435 types of drugs, with previous procurement methods focusing on "price for volume," which negatively impacted profitability and quality for some companies [2]

Macro Insights - July manufacturing PMI decreased by 0.4 percentage points to 49.3%, influenced by adverse weather conditions [6][8] - Manufacturing prices have begun to stabilize and rise due to ongoing capacity governance policies [8] - There is a need to further expand domestic demand, particularly in investment [8] Political Meeting Insights - The July Politburo meeting emphasized improving policy quality and effectiveness for the second half of the year [10][11] - The meeting highlighted the importance of consumer demand and stabilizing livelihoods, suggesting a focus on demand-side policies [13] - Policies to combat "involution" and promote collaboration between government and enterprises were also discussed [12] Fixed Income Insights - The July PMI data indicates a supply-demand decline, with the price index continuing to rise [16][18] - The manufacturing PMI remains below the expansion threshold for four consecutive months, reflecting weak seasonal performance [17] - The bond market is expected to enter a narrow fluctuation phase, with limited incremental policies [20] Computer Industry Insights - The AI application continues to progress, with significant growth in overseas tech giants driven by AI [22][25] - Domestic AI applications are expected to see increased monetization as models improve [25] - Key investment targets include companies like Kingdee International and Yonyou Network in the domestic AI application space [25] Pharmaceutical Industry Insights - Guobang Pharmaceutical reported a revenue of 3.026 billion yuan in the first half of 2025, a 4.63% increase [31] - The animal health segment saw a significant revenue increase of 53.5%, driven by strong sales of core products [32] - The company is expanding into new areas such as plant protection and health products, indicating a long-term growth strategy [32] Market Strategy Insights - The report suggests focusing on innovative drugs, AI hardware, and military-related themes for investment opportunities [36] - The macro policy environment is expected to support long-term investments in specialized and innovative enterprises [36] - Investors are advised to look for structural opportunities in growth-oriented companies with core technological advantages [36]

Group 1 - The pharmaceutical sector experienced a significant surge on August 1, with multiple stocks hitting the daily limit up, including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Hanchang Group [1] - Yuekang Pharmaceutical saw an increase of over 12%, while Weikang Pharmaceutical rose by more than 9% [1]

Group 1 - The core focus of the article highlights the volatility in the stock market, particularly with AI stocks and the contrasting actions of institutional investors and retail investors [1] - The AI stock "Yidian Tianxia" saw a significant surge, with a 20% limit up and a 37.61% turnover rate, attracting 3.75 billion in buying from various investors [3] - Institutional investors are actively trading in "Xizang Tianlu," showing a back-and-forth dynamic with net selling and buying, indicating speculative trading based on policy expectations [3] Group 2 - Nord Shares, a player in solid-state battery technology, experienced a surge with foreign capital heavily investing, indicating confidence in high-end manufacturing and domestic substitution [4] - The article notes a significant retreat from retail investors in the pharmaceutical sector, with major sell-offs in stocks like "Yatai Pharmaceutical" and "Dezhan Health" [4][5] - The article advises caution for retail investors, suggesting they should be quick to act on trends like AI and high-end manufacturing while avoiding speculative plays in policy-driven stocks [6]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海毕得医药科技股份有限公司 法律意见书 国枫律股字[2025] A0378 号 致：上海毕得医药科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 宜，出具本法律意见书。 网络投票结 ...

关注、加星，第一时间接收推送！ 文 | 赵伟、贾东旭、侯倩楠 联系人 | 贾东旭 摘要 中央财经委会议提出"统一政府行为尺度"，为"反内卷"赋予新内涵。相比过往，本轮 "内卷" 中地方政府 为何成为主要驱动因素，其行为逻辑具体表现在哪些制度性层面？系统分析，供参考。 一、本轮"反内卷"，有何不同？政策更聚焦地方政府行为规范。 相较于 2015 年中央财经领导小组第十一次会议，2025 年中央财经委尤其强调对地方政府行为的规范。 对比两份通稿，后者更侧重规范地方政府行为，提出 "规范地方招商引资" 等具体举措。同时，会议将 "五统一、一破除" 调整为 "五统一、一开放"，核心变化体现在地方政府行为规范尺度与对外开放维度。 上述差异的形成，一方面源于 2015 年产能过剩的全局性特征，另一方面与本轮 "内卷式" 竞争中地方政 府的深度参与直接相关。 2015 年问题源于 "四万亿" 刺激后上游产业过度投资及当时的房地产下行压 力；《求是》文章指出，本轮地方政府的行为表现为打造政策洼地、盲目上马项目、设置市场壁垒。 具体来看，本轮 "内卷式" 竞争涉及的行业中，绝大多数需求呈改善或稳定态势，而非恶化趋势。 电气 机 ...

每经记者｜陈晴 每经编辑｜魏官红 并购重组 达瑞电子：拟以增资及股权收购方式取得维斯德80%股权 中国石化公告，按中国企业会计准则，预计公司2025年上半年实现归属于母公司股东的净利润为201亿 元至216亿元，与上年同期相比，将下降39.5%至43.7%。 青岛银行：2025年上半年归母净利润30.65亿元，同比增长16.05% 青岛银行公告，2025年上半年营业收入76.62亿元，同比增长7.50%；归母净利润30.65亿元，同比增长 16.05%。 增减持 达瑞电子7月31日晚间公告，公司拟以3000万元认购东莞市维斯德新材料技术有限公司新增注册资本 171.43万元，并以1.34亿元受让麦德坤、饶熙怡本次交易前持有的维斯德76.57%股权。本次交易完成 后，公司将持有维斯德80%股权。 济川药业：曹飞完成要约收购交割，直接及间接控制公司56.07%股份 济川药业7月31日公告称，曹飞要约收购公司股份已完成交割。交割完成后，曹飞直接及间接控制公司 股份合计5.17亿股，占公司总股本的56.07%。曹飞及其一致行动人曹龙祥共同控制公司5.64亿股股份， 占公司总股本的61.15%。 业绩披露 捷佳伟创：上 ...

Core Viewpoint - As of July 31, 2025, Kangtai Biological (300601) reported a closing price of 17.42 yuan, experiencing a decline of 1.86% with a turnover rate of 3.05% and a trading volume of 274,300 hands, amounting to 484 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, the company reported total operating revenue of 645 million yuan, representing a year-on-year growth of 42.85% [1] - The net profit attributable to shareholders was 22.43 million yuan, a decrease of 58.51% year-on-year [1] - The non-recurring net profit was 16.91 million yuan, showing a year-on-year increase of 17.56% [1] - The current ratio stood at 2.677, the quick ratio at 2.365, and the debt-to-asset ratio at 32.07% [1] Capital Flow - On the reporting day, the net outflow of main funds was 61.05 million yuan, accounting for 12.6% of the transaction value [1] - The net outflow from large orders was 17.58 million yuan, representing 3.63% of the transaction value, while small orders saw a net inflow of 46.24 million yuan, accounting for 9.55% [1] Company Overview - Shenzhen Kangtai Biological Products Co., Ltd. was established in 1992 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 11.17 billion yuan and a paid-in capital of 1.75 billion yuan [1] - The legal representative of the company is Du Weimin [1] Investment and Intellectual Property - The company has made investments in 6 enterprises and participated in 1,088 bidding projects [2] - It holds 13 trademark registrations and 57 patents, along with 418 administrative licenses [2]

Macro Dynamics - The State Administration for Market Regulation will convert the pilot commission into a formal commission for conducting antitrust reviews of certain operator concentrations from August 1, 2025, after a successful pilot period from August 1, 2022, to July 31, 2025 [1] Financial Institutions - Zheng Yu has officially taken on the roles of Party Secretary, Chairman, and General Manager of Wukuang Securities, having previously served in various positions within the company [5] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half of 2025, representing a year-on-year increase of 16.05%, with total operating income of 7.662 billion yuan, up 7.5% [6] Market Data - On July 31, the three major indices fell by over 1%, with the Shanghai Composite Index down 1.18%, the Shenzhen Component Index down 1.73%, and the ChiNext Index down 1.66%. The total market turnover approached 2 trillion yuan, with over 4,200 stocks declining [7] - The financing balance of the two markets increased by 2.168 billion yuan, with the Shanghai Stock Exchange's balance at 1,001.228 billion yuan and the Shenzhen Stock Exchange's balance at 963.026 billion yuan [9] Company Dynamics - Industrial Fulian announced that there have been no significant changes in its main customers and products amid recent stock price fluctuations [13] - Sinopec expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year, due to factors such as a significant drop in international oil prices and intense market competition [14] - Heng Rui Medicine received approval for clinical trials of HRS-5041, a new drug for prostate cancer treatment, which shows potential in overcoming resistance compared to second-generation AR inhibitors [16]